Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Laronde

Request full access

Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)

Cambridge, United StatesFounded 2017Biotech & Life Sciences

About Laronde

Laronde was established in 2017 as a venture by Flagship Labs, the innovation division of Flagship Pioneering. The company, initially designated FL50, originated from explorations into the therapeutic potential of long non-coding RNA (lncRNA) that began the same year. This research was spearheaded by a team led by Avak Kahvejian, Ph.D., a General Partner at Flagship Pioneering who also served as Laronde's founding CEO. The scientific inquiry into naturally occurring circular RNA in mammalian cells led to the creation of Endless RNA™ (eRNA).

The company's core technology, Endless RNA™ (eRNA), is a synthetically engineered, closed-loop RNA designed to be programmable for expressing therapeutic proteins within the body. Unlike linear messenger RNA (mRNA), eRNA's circular structure protects it from being broken down by exonuclease enzymes, which typically dismantle RNA strands from their ends. This structural feature is intended to provide high stability and a prolonged therapeutic effect. The name "Laronde" itself is derived from the French word for "round," highlighting the importance of this circular architecture. Furthermore, eRNA is designed to be non-immunogenic, meaning it avoids triggering the body's innate immune system, which allows for the possibility of repeat dosing.

Laronde's business model is centered on developing a new class of programmable medicines. The eRNA platform is modular, allowing for the "protein-coding cassette" to be switched out to produce different proteins, such as peptides, enzymes, and antibodies. This adaptability positions the company to address a wide spectrum of diseases, with initial areas of interest including hematology, oncology, neurology, and immunology. The firm operates as a biopharmaceutical platform company, aiming to create a portfolio of drug programs. Its strategy involves not only developing and commercializing its own medicines but also potentially selling or spinning out certain programs. A significant milestone was achieved in August 2021, when Laronde secured $440 million in a Series B financing round from a syndicate of investors, including its founder Flagship Pioneering.

Source: Dealroom company data

At a glance

Status
Operational
Employees
43
Open positions
None listed
Dealroom signal
62.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Synthetic Biology, RNA, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Oct 2023
Capital deployed
—
Preferred round
MERGER

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
MERGEROther financing Oct 2023 $0 — Senda Biosciences ↗
SERIES BOther financing Aug 2021 $440M $1.8B BlackRock · Fidelity Investments · CPP Investments · Federated Hermes —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Laronde website traffic

Latest recorded traffic for Laronde is 4.1K monthly website visits, up 2.5% over the last three months. Laronde's team grew 0% over the past year.

Latest monthly visits4.1K 3-month web change+2.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Laronde in the Cambridge ecosystem

Live from Dealroom

The Laronde office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Other known investors1 additional known investor

  • Senda Biosciences
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Laronde’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.